基于核体的候选疫苗OVX033在一个仓鼠挑战模型中提供了针对SARS-CoV-2变体的宽频保护
Charlotte Primard1, Elodie Monchâtre-Leroy2, Judith Del Campo1
1Osivax, Lyon, France.
Frontiers in immunology
|July 6, 2023
概括
一种新的核体 (N) 蛋白候选疫苗OVX033提供了对SARS-CoV-2变种的广泛保护. 这种疫苗触发T细胞反应,并降低了仓鼠模型中的疾病严重程度,显示了未来COVID-19疫苗的前景.
科学领域:
- 病毒学 病毒学
- 疫苗学 疫苗学 疫苗学
- 免疫学 免疫学 免疫学
背景情况:
- 目前的基于尖峰的COVID-19疫苗面临着挑战,对新出现的SARS-CoV-2变种的疗效正在下降.
- 核囊体 (N) 蛋白在整个萨尔贝科病毒中呈现着保存的抗原标,为更广泛的疫苗覆盖提供了潜力.
研究的目的:
- 为了评估OVX033,一个重组的SARS-CoV-2 N蛋白与oligoDOM融合,作为一种针对sarbecoviruses广泛保护的疫苗候选人.
- 评估OVX033在临床前的仓鼠模型中对SARS-CoV-2变体的免疫性和保护效果.
主要方法:
- 针对SARS-CoV-2核体 (N) 蛋白的重组蛋白质疫苗OVX033是使用oligoDOM自组装域开发的.
- 采用仓鼠挑战模型来评估对SARS-CoV-2变种 (B.1,Delta,Omicron) 的交叉保护.
- 通过体重减轻,肺病毒载荷和组织病理学评估来衡量有效性.
主要成果:
- OVX033诱导的交叉反应性T细胞反应.
- 用OVX033接种疫苗的仓鼠对三种SARS-CoV-2变种显示出显著的交叉保护.
- 与对照群相比,接种疫苗的仓鼠体重减轻,肺部病毒负载降低,肺部组织损伤减少.
结论:
- OVX033证明了作为一种广泛保护SARS-CoV-2及其变种的疫苗候选人的潜力.
- 基于N蛋白质的疫苗引起了强大的细胞免疫力,并在相关的动物模型中提供了保护.
- 进一步开发OVX033可能会为抗击COVID-19的现有基疫苗提供替代或补充策略.
相关概念视频
01:25Inhibitors Of Virion Release
Viral replication and dissemination rely on efficient mechanisms for host cell entry, genome replication, assembly, and release. Influenza viruses, such as types A and B, are negative-sense single-stranded RNA viruses with a segmented genome, that depend on two critical surface glycoproteins to carry out these processes: hemagglutinin (HA) and neuraminidase (NA). HA initiates infection by binding to sialic acid residues on the surface of host epithelial cells, facilitating receptor-mediated...
01:19Inhibitors of Virion Maturation and Assembly
As part of their replication cycle, certain viruses synthesize long precursor proteins called polyproteins within infected host cells. In human immunodeficiency virus (HIV), two major polyproteins are produced: Gag and Gag-Pol. The Gag polyprotein supplies the structural components of the virus, while Gag-Pol includes essential viral enzymes such as reverse transcriptase, integrase, and protease. After synthesis, these polyproteins move to the host cell membrane, where they assemble into an...